Cancer Drugmaker iTeos to Shut Down

Post-TIGIT flop, iTeos Therapeutics is shuttering

Today's biotech news includes more biopharma trials happening only in China, Merck and Daiichi Sankyo withdrawing an FDA application, etc.

Cancer drugmaker iTeos to shut down

Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off its assets and intellectual property in a bid to "maximize" shareholder value.

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure - Pharmaceutical Technology

iTeos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.

Weeks after TIGIT fail, iTeos decides to wind down

Only 15 days after saying it was searching for strategic alternatives, iTeos Therapeutics' board has determined its answer: It will be shutting down. The move comes quickly after GSK and iTeos ...

15:25 The Walloon biotech company, which earlier this month pulled the plug on a collaboration with British pharmaceutical giant GSK, is initiating the Renault procedure for collective dismissals.

iTeos plans to shut down operations after cancer therapy setback - Regional Media News

(Reuters) -Drug developer iTeos Therapeutics said on Wednesday it plans to wind down its operations and explore selling its assets, including experimental cancer treatments and an obesity program. Earlier this month, Britain’s GSK and iTeos Therapeutics said they have stopped developing an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing in two studies. (Reporting by Kamal Choudhury in Bengaluru; E…